ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0432

Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
Abstract Number: 0433

Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey
Abstract Number: 0434

Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis
Abstract Number: 0435

Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071
Abstract Number: 0436

Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases
Abstract Number: 0437

Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Abstract Number: 0438

Rheumatological Immune-Related Adverse Events of Immune Checkpoint Inhibitors Based on the FDA Adverse Event Reporting System
Abstract Number: 0439

Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
Abstract Number: 0440

Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Abstract Number: 0441

A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Abstract Number: 0442

Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
Abstract Number: 0443

Safety and Efficacy of Belimumab in the Treatment of Adult Idiopathic Inflammatory Myositis (Polymyositis and Dermatomyositis)
Abstract Number: 0444

COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
Abstract Number: 0445

Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
Abstract Number: 0446

Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].